Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cognizant Technology Solutions Corp (CTSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Cognizant Technology Solutions CorpTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Cognizant Technology Solutions Corp vs Neurocrine Biosciences Inc — how do they compare? Cognizant Technology Solutions Corp trades at $57.72 (market cap $26.40B), while Neurocrine Biosciences Inc trades at $157.15 (market cap $16.46B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

CTSHNBIX
Market Cap
$26.40B$16.46B
Sector
TechnologyHealth
52-Week High
$86.70$185.50
52-Week Low
$38.73$123.10
Enterprise Value
$27.44B$16.48B
Dividend Yield
2.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cognizant Technology Solutions Corp

CTSH trades at $57.76, down 0.94% on the day, with a bullish technical signal and strong cash flow generation. Recent Q2 2026 earnings missed estimates, but revenue beat, and the company maintains solid profitability with a 10.26% net margin. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience in financial services growth amid AI investments.

The outlook remains cautiously optimistic with upside potential from AI initiatives and large-deal execution, though risks include client spending caution and competitive pressures. Valuation metrics like a P/E of 12.58 suggest room for growth if earnings momentum improves.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cognizant Technology Solutions Corp

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Read more on CTSH

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX